Stock Report

All about this stock under one free report Last Updated: 23-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Krebs Biochemicals Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: KREBSBIO | BSE: 524518

₹57.48

up-down-arrow ₹1.42 (2.53%)

As on 22-Oct-2026IST

Market cap

info icon

₹125 Cr

Revenue (TTM)

info icon

₹25 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

-0.8

Div. Yield

info icon

0 %

Edit peer-selector-edit
Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 125 33,864 24,283 15,561 13,298
Revenue (₹ Cr)
 25 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 -14.10 1,018.97 497.77 603.02 270.18
Net Margin (%)
 -51.43 10.47 20.72 22.63 23.29
RoE (%)
 -- 21.30 28.49 19.61 14.45
Price to Earnings
 -- 33.48 48.78 25.81 48.29
Price-To-Book
 -0.75 6.47 12.01 4.47 6.41

Income Statement (₹ Cr)

Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
25.23 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
27.41 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
27.77 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
-2.54 1,943.92 762.90 836.69 388.38
Depreciation arrow
6.41 425.10 98.11 78.88 74.78
EBIT arrow
-8.95 1,518.82 664.79 757.81 313.60
Interest arrow
7.32 148.45 26.33 5.43 0.26
Other Income arrow
2.17 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
-14.10 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
0.00 370.94 171.48 197.53 91.39
Profit after Tax arrow
-14.10 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
-162.75 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
212.94 723.57 345.47 142.73 50.51
Current Liabilities arrow
113.07 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
163.25 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
143.30 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
9.62 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
163.25 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
224.84 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
-103.44 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
9.26 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-1.92 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-3.64 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
5.54 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-0.01 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
-15.38 25.25 27.50 24.61 18.04
ROE (%) arrow
0.00 21.30 28.49 19.61 14.45
ROA (%) arrow
-8.48 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
-35.47 15.68 28.03 29.25 28.29
Net Margin (%) arrow
-51.43 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
-29.72 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
58.40 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
47.97 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
47.97 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
-11.29 11.36 22.95 18.43 11.27

Valuation Ratios

 Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
-8.84 32.79 48.78 24.99 47.87
Price / Book Value arrow
-0.75 6.47 12.01 4.47 6.41
Dividend Yield (%) arrow
0.00 0.20 0.18 0.39 0.59
EV/EBITDA arrow
-137.68 17.96 31.62 17.66 33.17
Market Cap (₹ Cr) arrow
86.26 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
-1.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
-0.38 0.16 -- -- --
Current Ratio arrow
0.09 1.43 2.09 5.21 7.39
Quick Ratio arrow
0.03 0.82 1.37 3.85 5.46
Interest Coverage arrow
-0.93 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Krebs Biochemicals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
0.02 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.15 1.09 0.93 0.70 0.52
Receivable days arrow
0.42 88.68 77.32 144.58 169.86
Inventory Days arrow
90.24 84.11 80.83 96.67 97.92
Payable days arrow
0.00 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
90.66 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...